Thus, PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles are a promising non-viral gene therapy for Stargardt disease type 1 (STGD1) [13]. Here, ABCA4 is linked to severe early-childhood-onset retinal dystrophy.